cohbar.JPG
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
July 12, 2022 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
cohbar.JPG
CohBar to Participate at Upcoming Conferences in June 2022
June 07, 2022 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
cohbar.JPG
CohBar to Present at the H.C. Wainwright Global Investment Conference
May 19, 2022 16:02 ET | CohBar, Inc.
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
cohbar.JPG
CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
May 16, 2022 16:01 ET | CohBar, Inc.
MENLO PARK, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
cohbar.JPG
CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal
May 12, 2022 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides...
cohbar.JPG
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
May 02, 2022 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
cohbar.JPG
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 29, 2022 16:01 ET | CohBar, Inc.
MENLO PARK, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
cohbar.JPG
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
March 15, 2022 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its...
cohbar.JPG
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
January 03, 2022 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its...
cohbar.JPG
CohBar Announces Changes to its Board of Directors and R&D Leadership
December 17, 2021 09:00 ET | CohBar, Inc.
Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE...